Abstract
We consider an SIR-type model of immunological behaviour for HIV dynamics, including the effects of reverse transcriptase inhibitors and other drugs which prevent cellular infection. We use impulsive differential equations to model drug behaviour. We classify different regimes according to whether the drug efficacy is negligible, intermediate or high. We consider two strains of the virus: a wild-type strain that can be controlled by both intermediate and high drug concentrations, and a mutant strain that can only be controlled by high drug concentrations. Drug regimes may take trajectories through one, two or all three regimes, depending on the dosage and the dosing schedule. We demonstrate that drug resistance arises at both intermediate and high drug levels. At low drug levels resistance does not emerge, but the total T cell count is proven to be significantly lower than in the disease-free state. At intermediate drug levels, drug resistance is guaranteed to emerge. At high drug levels, either the drug-resistant strain will dominate or, in the absence of longer-lived reservoirs of infected cells, both viral sub-populations will be cleared. In the latter case the immune system is maintained by a population of T cells which have absorbed sufficient quantities of the drug to prevent infection by even the drug-resistant strain. We provide estimates of a range of dosages and dosing schedules which would, if physiologically tolerable, theoretically eliminate free virus in this system. Our results predict that to control viral load, decreasing the interval between doses is more effective than increasing the dose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Austin, D.J., Anderson, R.M., 1999. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos. Trans. R. Soc. Lond. B 354, 721–738.
Austin, D.J., White, N.J., Anderson, R.M., 1998. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194, 313–339.
Bainov, D.D., Simeonov, P.S., 1989. Systems with Impulsive Effect. Ellis Horwood Ltd, Chichester.
Bainov, D.D., Simeonov, P.S., 1993. Impulsive Differential Equations: Periodic Solutions and Applications. Longman Scientific and Technical, Burnt Mill.
Bainov, D.D., Simeonov, P.S., 1995. Impulsive Differential Equations: Asymptotic Properties of the Solutions. World Scientific, Singapore.
Bonhoeffer, S., Nowak, M.A., 1997. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. R. Soc. Lond. B 264, 631–637.
Coffin, J.M., 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267, 483–489.
de Boer, R.J., Boucher, C.A., 1996. Anti-CD4 therapy for AIDs suggested by mathematical models. Proc. R. Soc. Lond. B 263, 899–905.
de Boer, R.J., Perelson, A.S., 1998. Target cell limited and immune control models of HIV infections: a comparison. J. Theor. Biol. 190, 201–214.
de Jong, M.D., Veenstra, J., Stilianakis, N.I., Schuurman, R., Lange, J.M., de Boer, R.J., Boucher, C.A., 1996. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proc. Natl. Acad. Sci. 93(11), 5501–5506.
Frost, S.D.W., McLean, A.R., 1994. Germinal centre destruction as a major pathway of HIV pathogenesis. J. AIDS 7, 236–244.
Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M., 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373(6510), 123–126.
Hoggard, P.G., Back, D.J., 2002. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transport molecules. Curr. Opin. Infect. Dis. 15, 3–8.
Huang, Y., Rosenkranz, S.L., Wu, H., 2003. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math. Biosci. 184, 165–186.
Kepler, T.B., Perelson, A.S., 1998. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl. Acad. Sci. USA 95, 11514–11519.
Kirschner, D.E., Webb, G.F., 1996. A model for the treatment strategy in the chemotherapy of AIDS. Bull. Math. Biol. 58, 367–391.
Lakshmikantham, V., Bainov, D.D., Simeonov, P.S., 1989. Theory of Impulsive Differential Equations. World Scientific, Singapore.
Lipsitch, M., Levin, B.R., 1998. The population dynamics of tuberculosis chemotherapy: mathematical models of the roles of noncompliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis. 2, 187–199.
McLean, A.R., Nowak, M.A., 1992. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 6, 71–79.
Nowak, M.A., Anderson, R.M., McLean, A.R., Wolfs, T.F., Goudsmit, J., May, R.M., 1991. Antigenic diversity thresholds and the development of AIDS. Science 254, 963–969.
Nowak, M.A., Bonhoeffer, S., Shaw, G.M., May, R.M., 1997. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184, 203–217.
Perelson, A.S., 2002. Modelling viral and immune system dynamics. Nat. Rev.: Immunol. 2, 28–36.
Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., Ho, D.D., 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188–191.
Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., Ho, D.D., 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582–1585.
Ribeiro, R.M., Bonhoeffer, S., 2000. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97, 7681–7686.
Smith, R.J., Wahl, L.M., 2004. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 66(5), 1259–1283.
Stilianakis, N.I., Boucher, C.A., de Jong, M.D., Van Leeuwen, R., Schuurman, R., de Boer, R.J., 1997. Clinical data sets on human immunodeficiency virus type 1 reverse transcriptase resistant mutants explained by a mathematical model. J. Virol. 71, 161–168.
Wahl, L.M., Nowak, M.A., 2000. Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. Lond. B 267, 835–843.
Wein, L.M., D’Amato, R.M., Perelson, A.S., 1998. Mathematical considerations of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J. Theor. Biol. 192, 81–98.
Wodarz, D., 2001. Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. J. Theor. Biol. 213, 447–459.
Wodarz, D., Nowak, M.A., 1999. Specific therapy regimes could lead to long-term immunological control of HIV. Proc. Natl. Acad. Sci. USA 96, 14464–14469.
Wodarz, D., Page, K., Arnaout, R., Thomsen, A.R., Lifson, J.D., Nowak, M.A., 2000. A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment. Philos. Trans. R. Soc. Lond. B 355, 329–343.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Smith, R.J., Wahl, L.M. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 67, 783–813 (2005). https://doi.org/10.1016/j.bulm.2004.10.004
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/j.bulm.2004.10.004